<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03184727</url>
  </required_header>
  <id_info>
    <org_study_id>2016YFC1304405</org_study_id>
    <nct_id>NCT03184727</nct_id>
  </id_info>
  <brief_title>Pulmonary Vasculature and Right Heart Dysfunction in Chronic Obstructive Pulmonay Disease</brief_title>
  <official_title>Pulmonary Vasculature and Right Heart Dysfunction in Chronic Obstructive Pulmonay Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pulmonary vasculopathy and right heart dysfunction in COPD are drawing increasing
      attention these days. Recent researches show that pulmonary vasculopathy and right heart
      dysfunction relate to greater severity in COPD. Applying appropriate modalities for early
      detection of pulmonary vasculopathy and right heart dysfunction is of great importance.
      What's more, the interaction mechanism between pulmonary vasculature, right heart and COPD
      still needs to be further studied. The aim of our study is to develop an assessment system of
      pulmonary vasculopathy and right heart dysfunction in COPD patients and elucidate their
      impact on COPD course and outcome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>3 years</time_frame>
    <description>survival rate in %</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>COPD exacerbations</measure>
    <time_frame>3 year</time_frame>
    <description>total times</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GOLD degree</measure>
    <time_frame>3 year</time_frame>
    <description>Ⅰ-Ⅳ according to the pulmonary function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA degree</measure>
    <time_frame>3 year</time_frame>
    <description>Ⅰ-Ⅳ according to the symptom</description>
  </secondary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>COPD</condition>
  <condition>Pulmonary Vascular Disorder</condition>
  <condition>Right Ventricular Dysfunction</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum and blood cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        stable COPD patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  stable COPD patients

        Exclusion Criteria:

          -  patents with other respiratory diseases and pulmonary hypertension other than group 3
             PH;

          -  psychopath, addict or patients not able to coordinate;

          -  patients in pregnancy or breastfeeding;

          -  patients with limited life expectancy;

          -  patients with contraindiction for MRI or PET;

          -  patients having cerebrovascular events in 3 months;

          -  unstable COPD patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianguo He He, MD</last_name>
    <phone>80-10-88398060</phone>
    <email>hejianguofw@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiovascular Institute and Fu Wai Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianguo He, MD</last_name>
      <phone>86 01088398060</phone>
      <email>hejianguofw@163.com</email>
    </contact>
    <investigator>
      <last_name>Jianguo He, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2017</study_first_submitted>
  <study_first_submitted_qc>June 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>Jianguo He</investigator_full_name>
    <investigator_title>Chief of Pulmonary Vascular Disease Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Right</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

